Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-06: Perioperative Hydrocortisone in Partial Pancreatectomy
NCT07796997Phase 1Not yet recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydrocortisone in pancreatic cancer (PC), duodenal cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by University of Illinois Chicago. Primary endpoint: Incidence of postoperative pancreatic fistula at 30 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
hydrocortisone
03
Conditions
pancreatic cancer (PC)duodenal cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07796997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796997.